Siemens Healthineers launches capillary testing menu on Atellica analyzers
September 2026—Siemens Healthineers has launched capillary testing on the Atellica CH, IM, and CI analyzers after receiving the CE mark for 24 capillary blood testing claims.
Webinars and Sponsored Roundtables — Register Now
Tuesday, November 3, 2026, 1 PM-2 PM ET
Hear an expert discuss the challenges of detecting NRG1 fusions and how RNA-based testing can support more comprehensive fusion identification in clinical practice.
Webinar presenter Benjamin Weinberg, MD, Associate Professor of Medicine and Attending Physician
specializing in gastrointestinal medical oncology
CAP TODAY does not endorse any of the products or services named within. The webinar is made possible by a special educational grant from Diaceutics.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Tuesday, November 10, 2026, 1 PM-2 PM ET
Join us for a session to help improve diagnostic accuracy in your practice when scoring HER2 IHC 0 with faint, incomplete membrane staining in ≤10% of tumor cells vs IHC 0 with no membrane staining detected in patients with mBC.
Webinar presenter Jeffrey Gregg, MD, University of Nevada
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Monday, November 16, 2026, 12:30 PM-2 PM ET
Hear experts discuss a multidisciplinary approach to oncopathology for HER2
assessments for solid tumors in the absence of a companion diagnostic.
Webinar presenters Funda Meric-Bernstam, MD, Chair, Department of Investigational Cancer Therapeutics Medical Director, Institute for Personalized Cancer Therapy, The University of Texas MD Anderson Cancer Center, Houston, Texas, and Emina E. Torlakovic, MD, PhD, College of Medicine, University of Saskatchewan, Canadian Biomarker Quality Assurance, Saskatoon, Saskatchewan, Canada, and Carol Cheung, MD, PhD, JD, FRCPC, Deputy Director, Canadian Biomarker Quality, Assurance—Programme canadien d’assurance de la qualité des biomarqueurs
CAP TODAY does not endorse any of the products or services named within. This program is being sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Wednesday, December 9, 2026, 12 PM-1 PM ET
Hear an expert pathologist discuss the role of HER2 IHC testing and scoring in solid tumors including endometrial, ovarian, cervical, bladder, non-small cell lung, colorectal, and biliary cancers
Webinar presenter Michelle Shiller, DO, MSPT, Baylor Sammons Cancer Center; Fulgent Genetics; Texas Cancer Interception Institute
CAP TODAY does not endorse any of the products or services named within. This program is intended for US healthcare professionals. This program is being sponsored by AstraZeneca. The speaker is being compensated for the presentation. The program is not CME accredited and may not be used for CME accreditation.
Moderated by: Bob McGonnagle, Publisher, CAP TODAY
Subspecialties
Interactive Product Guides
Marketplace
FDA clears PrecivityAD2 test
September 2026—The FDA has cleared C2N Diagnostics’ PrecivityAD2 test, indicated for use in adults aged 40 years and older who present with signs or symptoms of cognitive impairment undergoing evaluation for Alzheimer’s disease or other forms of cognitive decline.
NEB releases Monarch Mag cfRNA extraction kit
September 2026—New England Biolabs released the Monarch Mag Cell-free RNA Extraction kit, which enables isolation of low-abundance cfRNA and exome-associated RNA from biofluids including plasma, serum, urine, and cerebrospinal fluid.
Seegene analysis shows limits of single-pathogen respiratory testing
September 2026—Seegene has released findings from an analysis of approximately 260,000 pediatric respiratory PCR test results collected over 42 months from children aged zero to five years.
FDA approves Freenome SimpleScreen CRC test
September 2026—The FDA has approved Freenome’s SimpleScreen CRC, a blood-based screening test for colorectal cancer in adults 45 and older who are at average risk for developing the disease.
FDA clears OraSure at-home urine collection kit on Roche Cobas systems
September 2026—The FDA has cleared OraSure Technologies’ Colli-Pee Dx Urine Collection kit for use with Roche’s tests for Chlamydia trachomatis, Neisseria gonorrhoeae, Trichomonas vaginalis, and Mycoplasma genitalium on the Roche Cobas 5800, 6800, and 8800 molecular diagnostic systems.
Streck launches MDx-Chex for respiratory testing
September 2026—Streck has released its MDx-Chex for RP molecular quality control designed for high-plex respiratory testing panels.
New York approves Haystack MRD test
September 2026—The New York State Clinical Laboratory Evaluation Program has approved Quest Diagnostics’ Haystack MRD test.
Leica Biosystems expands collaboration with AstraZeneca, Daiichi Sankyo
September 2026—Leica Biosystems has expanded its collaboration with AstraZeneca and Daiichi Sankyo to develop an immunohistochemistry assay and image analysis algorithm for the TROP2 normalized membrane ratio biomarker in non-small cell lung cancer, for use as a research tool only.
Quest extends oncology test access through OncoEMR MPI
September 2026—Quest Diagnostics is integrating its Haystack MRD ctDNA test and comprehensive genomic profiling services for solid tumor cancers within OncoEMR, an EHR from Flatiron Health, via a pilot program with American Oncology Network and other community oncology providers.